Can we ignore minimal hepatic encephalopathy any longer?

Hepatology

Volumn 45, Issue 3, 2007, Pages 547-548

  Qadri, Asif M ^a   Ogunwale, Ben O ^a   Mullen, Kevin D ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LACTULOSE; PROBIOTIC AGENT;

ANAMNESIS; EDITORIAL; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MENTAL HEALTH; PREVALENCE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

DISACCHARIDES; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; INCIDENCE; LACTULOSE; PSYCHOMETRICS; QUALITY OF LIFE; RIFAMYCINS;

EID: 33947387582     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21617     Document Type: Editorial

References (15)

1. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive function and health-related quality of life in cirrhotic patients with minimal hepatic encephalopathy. HEPATOLOGY 2007;45:549-559.
2. Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-Bot ML, Hop WC, et al. Subclinical hepatic encephalopathy impairs daily functioning. HEPATOLOGY 1998;28:45-49.
3. Marchesini G, Bianchi G, Salerno F, Merli M, Panella C, Loguercio C, et al. and the Italian Study Group for quality of life in cirrhosis. Factors associated with poor health-related quality of life in patients with cirrhosis. Gastroenterology 2001;120:170-178.
4. Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. HEPATOLOGY 1997;6:1410-1414.
5. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000;45:1549-1552.
6. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition; nomenclature, diagnosis and quantification. Final report of the working party at the 11th World Congress of Gastroenterology, Vienna 1998. HEPATOLOGY 2002;35: 716-721.
7. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004;19:253-267.
8. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001;16:531-535.
9. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Symbiotic modulation of gut flora: effect of minimal hepatic encephalopathy in patients with cirrhosis. HEPATOLOGY 2004;39:1441-1449.
10. Ingraham LJ, Aken CB. An empirical approach to determining criteria for abnormality and test batteries for multiple measures. Neuropsychology 1996;10:120-124.
11. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34:768-773.
12. Mullen KD, Cole M, Foley JM. Neurological deficits in "awake" cirrhotic patients on hepatic encephalopathy treatment: missed metabolic or metal disorder? Gastroenterology 1996;111:256-257.
13. Als-Nielsen B, Gluud L, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systemic review of randomised trials. BMJ 2004; 328:1046.
14. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V, et al. Comparison of rifaxamin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58.
15. Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States: An AASLD Survey. HEPATOLOGY 2007;45:833-834.